Mogling Bio

Mogling Bio develops pharmacological solutions to restore the function of aged and exhausted stem cells by targeting the overactivation of the Cdc42 protein. The company's platform aims to treat age-related diseases such as osteoporosis, immune dysfunction, and neurodegeneration by reversing cellular architecture decline. Their therapeutic approach focuses on extending healthspan and compressing morbidity through regenerative medicine.